Dozens of states and the federal government filed a False Claims Act lawsuit alleging that Novartis paid kickbacks to specialty pharmacy chains, including AmerisourceBergen, to boost sales of Novartis’s drugs, including Gleevec, Exjade, Tasigna, Tobramycin Inhalation Solution (TOBI), and Myfortic. Novartis allegedly offered financial inducements such as referrals of patients, rebates, and discounts in exchange for the pharmacies’ agreement to recommend and increase the sales of Novartis specialty drug products and to take steps to capture an increased market share for Novartis’ products. As a result, the lawsuit alleged Novartis knowingly caused the pharmacies to submit hundreds of millions of dollars in false claims to publicly-funded health care programs. In November 2015, Novartis reached a $390 million settlement with the Department of Justice, all intervening states, and the individual who originally filed the lawsuit.